Sign up USA
Proactive Investors - Run By Investors For Investors

Moleculin Biotech bolstered by FDA decision on its brain tumor drug

The FDA agreed its Investigational New Drug (IND) application for a Phase I trial of drug WP1066
Moleculin Biotech bolstered by FDA decision on its brain tumor drug
The human brain..

Moleculin Biotech Inc (NASDAQ:MBRX) shares surged over 16% to US$2.12 as it announced key FDA news for its brain cancer drug.

Its physician-sponsored Investigational New Drug (IND) application for a Phase I trial of drug WP1066 in patients with recurrent malignant glioma and brain metastasis from melanoma has been allowed by the US Food and Drug Administration, it said.

"We are so pleased to now have a second drug enter the clinical stage," said Walter Klemp, chairman and chief executive of Moleculin.

"We believe WP1066 represents a new class of anticancer drugs able to fight tumors on two fronts by directly inhibiting cell signaling supporting tumor activity, and independently stimulating a natural immune response.

"This constitutes a new approach to treating brain tumors and tumor metastasis to the brain.

View full MBRX profile View Profile

Moleculin Biotech Inc Timeline

Related Articles

Laboratory
June 21 2018
Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India
spreadsheet and calculator
January 25 2018
According to one City number cruncher, Ergomed’s drugs safety unit alone is worth as much as the whole business
mri scanner
June 06 2018
It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntington’s and multiple sclerosis
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use